Regeneron Pharmaceuticals To Buy 23andMe and Its Data For $256 Million
Regeneron Pharmaceuticals is acquiring most of 23andMe’s assets for $256 million. The sale includes 23andMe’s Personal Genome Service, Total Health and Research Services business lines. What’s not included is 23andMe’s… Weiterlesen »Regeneron Pharmaceuticals To Buy 23andMe and Its Data For $256 Million